Table 2:
Clinical outcomes and opioid prescription patterns by opioid prescribing cohort
| Outcome variable | Pre-implementation (n=113) | Post-implementation (n=160) | P-value |
|---|---|---|---|
| Median MED at discharge, mg (range) | 225 (75–450) | 112.5 (9–675) | <.001 |
| Discharge opioid prescription, n (%) | <.001 | ||
| 5 tablets of 5 mg oxycodone | 0 (0) | 43 (26.9) | |
| 15 tablets of 5 mg oxycodone | 1 (.9) | 56 (35) | |
| 30 tablets of 5 mg oxycodone | 87 (77) | 43 (26.9) | |
| Other | 25 (22.1) | 18 (11.3) | |
| Opioid refill provided, n (%) | 11 (9.7) | 18 (11.3) | .84 |
| Refills by # opioids prescribed, n (%)* | .036 | ||
| 5 tablets of 5 mg oxycodone | - | 3 (1.9) | |
| 15 tablets of 5 mg oxycodone | - | 4 (2.5) | |
| 30 tablets of 5 mg oxycodone | - | 10 (6.3) | |
| Other | - | 1 (.6) | |
| Median length of stay, days (range) | 3 (1–10) | 3 (1–10) | 1.0 |
| Readmission, n(%) | 8 (7.1) | 15 (9.4) | .66 |
| Readmission by # opioids prescribed, n (%)* | .61 | ||
| 5 tablets of 5 mg oxycodone | - | 2 (1.3) | |
| 15 tablets of 5 mg oxycodone | - | 7 (4.4) | |
| 30 tablets of 5 mg oxycodone | - | 4 (2.5) | |
| Other | - | 2 (1.3) |
Significant p-values signified in bold text
MED, morphine equivalent dose
*
Comparison between groups receiving 5, 10, and 15 tablets of oxycodone at discharge among prospective post-implementation cohort only